|
1. A method for suppressing the progression of, suppressing the recurrence of and/or treating pancreatic cancer or biliary tract cancer comprising administering nivolumab, as an active ingredient, in combination with FOLFIRINOX therapy or a dose-reducing regimen thereof to a subject in need thereof, wherein the administrating nivolumab does not include administrating nivolumab as a preoperative therapy, wherein the preoperative therapy is a preceding therapy with an anti-cancer drug prior to cancer resection surgery, and is performed for a purpose of preventing postoperative micrometastases of invasive cancer and preventing recurrence thereof, wherein nivolumab is administered at about 3 mg/kg body weight per dose or at about 240, 360, or 480 mg per dose about every 2 to 4 weeks, wherein the FOLFIRINOX therapy comprises administrations of oxaliplatin (L-OHP), irinotecan hydrochloride hydrate (CPT-11), levofolinate calcium (I-LV), and fluorouracil (5-FU), and wherein the dose-reducing regimen of the FOLFIRINOX therapy comprises a reduction of a dose of any of the L-OHP, CPT-11, I-LV, or 5-FU from the initial administration or in any of the administrations during the second and subsequent cycles of the FOLFIRINOX therapy.
|